Navigation Links
ADVENTRX Submits Exelbine™ New Drug Application
Date:11/3/2010

g developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use.  More information can be found on the Company's web site at www.adventrx.com.  

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on ADVENTRX's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding FDA acceptance of the Exelbine NDA for review, approval of Exelbine based on that 505(b)(2) NDA submission and patent protection for Exelbine. Actual events or results may differ materially from those expressed or implied by the forward-looking statements in this press release due to a number of risks and uncertainties, including, without limitation: the risk that the FDA does not accept the Exelbine NDA for review, including as a result of identifying clinical or nonclinical reasons for a refusal-to-file or identifying CMC reasons that were not identified in the refusal-to-file of the previously submitted Exelbine NDA; the potential that the bioequivalence data and other information included in the Exelbine NDA may not adequately support bioequivalence with Navelbine, including as a result of performing pharmacokinetic equivalence analyses based on a patient population other than the population on which ADVENTRX based its analysis; the potential that changes made in transferring the manufacturing process for Exelbine may result in a lack of comparability between the commercial product and the material used in the bioequivalence trial; the risk that results of future stability testing on samples of Exelbine do not support comparability between ADVENTRX's prior and intended commercial manufacturing sites or a commercially-viable expiration dating period; th
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... --  Vittamed Corporation , a neurodiagnostics medical device company based ... T. (Teo) Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, ... " Teo Forcht Dagi is an experienced ... venture capital," said Remis Bistras , President and CEO ... strategic, and entrepreneurial expertise to our Board." Dr. ...
(Date:8/29/2014)... 2014 Diseases largely eradicated in ... returning. Measles was declared eliminated in 2000, yet the ... August 15—the highest incidence in 20 years. In July, ... whooping cough a problem of "epidemic proportions." ... dying from these preventable diseases—in part because some parents ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... July 13 New England Biolabs (NEB) has expanded ... of NEBNext™ Quick DNA Sample Prep Reagent Set 2 and ... Roche,s 454 GS FLX Titanium™ and GS Junior™ instruments. These ... fast fragment library preparation. The Master Mix Set further streamlines ...
... July 13 Galen Advisors, a leading provider of ... for the first half of 2010.  Assaulted by rising costs, reduced ... expertise and automation of their revenue cycle. , ... Galen,s new clients include a ...
Cached Medicine Technology:New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms 2Galen Advisors Grows Client Base More Than 50% 2Galen Advisors Grows Client Base More Than 50% 3
(Date:8/31/2014)... August 31, 2014 Future Health, ... (EHR) software firm that focuses on helping doctors ... found a congruent commitment with the creators of ... , “We create an environment that assists doctors ... more time with patients,” says Steven Kraus, founder ...
(Date:8/31/2014)... Brook Forest Voices , audiobook ... & Sophistication: Short Stories of Wisdom and Kindness from ... James W. Jackson author, speaker, humanitarian and cultural economist. ... compresses his vast volume of meticulously handwritten notes taken ... countries on behalf of Project C.U.R.E . Founded ...
(Date:8/31/2014)... 2014 The severity of menopausal symptoms ... in menopause is expert in helping patients find ... from uncomfortable symptoms with the latest treatment options, including ... a variety of alternative treatments and products that can ... options may fall outside of what can be called ...
(Date:8/31/2014)... Barcelona, Spain Sunday 31 August 2014: Mortality ... at one year despite good use of oral anticoagulants, ... Atrial Fibrillation General Pilot Registry. The findings were presented ... by registry chairperson Professor Gregory Lip (Birmingham, UK). , ... sponsored registry focused on management practices of European cardiologists ...
(Date:8/30/2014)... August 2014: A new batteryless cardiac pacemaker based ... motion was presented at ESC Congress 2014 today ... does not require battery replacement. , Mr Zurbuchen, ... at ARTORG, University of Bern, Switzerland, said: "Batteries ... Once they reach a critically low energy level, ...
Breaking Medicine News(10 mins):Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 2Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 3Health News:Powerhouse EHR, Future Health, Announces Gold Sponsorship of POWERPlay in Sports National Tour 4Health News:Brook Forest Voices Announces End of Summer Release! Dr. James Jackson’s, “Simplicity & Sophistication” Audiobook 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 4Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 5Health News:AF mortality and morbidity high at 1 year despite good anticoagulant use 2Health News:Batteryless cardiac pacemaker is based on automatic wristwatch 2
... government and Delhi Public School (DPS) Society on a petition// ... 1.5 million for treatment of breast cancer. ,While ... Kapur's plea, Justice Hima Kohli asked Delhi's director of education ... 3. ,Kapoor pleaded to the court that she ...
... Center together with engineers from the university's Applied Physics ... checks a patient's finger for symptoms of Raynaud's disease. ... to be promising: ,The Ambulatory Raynaud's Monitor ... a bandage or medical tape. It contains two sensors ...
... The U.S. Food and Drug Administration (FDA) today ... Complex (Human), Alphanate. //The product is approved for ... Willebrand disease (vWD) in whom the hormone desmopressin ... approved for patients with severe vWD (Type 3) ...
... Delhi: All India Institute of Medical Sciences (AIIMS) director ... chief public relation officer filed a police complaint against ... public relation officer of AIIMS, has filed a police ... here accusing Venugopal of harassment, wrongful restraint from entering ...
... British scientists have developed a house to help people with ... a warning when it thinks there may be a problem. ... Institute of Medical Engineering could mean elderly people with fading ... rather than being forced to go into care homes, reported ...
... New Delhi: The Supreme Court Tuesday admitted a petition ... and use of non-iodised salt for human consumption. ... P.P. Naolekar and Justice R.V. Raveendran admitted the petition ... government to file its response in four weeks. ...
Cached Medicine News:Health News:Ex-teacher Sues Delhi Public School 2Health News:Space-Age Bandage Monitors Patients With Raynaud's Disease 2Health News:FDA Approves New Product to Treat Von Willebrand Disease 2Health News:AIIMS Official Files Complaint Against Venugopal 2Health News:‘Smart House’ Developed to Monitor People With Dement 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... Hoffmann® II Hybrid External Fixation System ... generation in hybrid fixation. It incorporates ... and is designed to offer speed ... patented Hoffmann® snap-fit technology. , ,Using ...
Medicine Products: